BACKGROUND: The substantial proportion of individuals with Parkinson's disease (PD) who have or are expected to develop concomitant cognitive impairment emphasizes the need for large, well-characterized participant cohorts to serve as a basis for research into the causes, manifestations, and potential treatments of cognitive decline in those with PD. OBJECTIVE: To establish a multi-site clinical core that cognitively and clinically characterizes patients with PD by obtaining quality longitudinal clinical, neuropsychological, and validated biomarker data. METHODS: Six hundred nineteen participants with idiopathic PD (68.0 ± 9.1 years, 7.1 ± 6.2 years since diagnosis, 70% males) were enrolled in the Pacific Northwest Udall Center (PANUC), one of the Morris K. Udall Centers of Excellence for Parkinson's Research, Clinical Consortium and underwent comprehensive clinical and neuropsychological assessment. Participants were diagnosed with no cognitive impairment (PD-NCI), mild cognitive impairment (PD-MCI), or dementia (PDD) at a diagnostic consensus conference. RESULTS: A substantial proportion of the overall sample was diagnosed with cognitive impairment at baseline: 22% with PDD and 59% with PD-MCI. A higher rate of cognitive impairment was observed in men than women (87% vs. 68%, p < 0.0001), despite a higher level of education. Most patients older than 50 years at the time of diagnosis and with disease duration greater than 10 years were cognitively impaired or demented. CONCLUSIONS: The PANUC Clinical Consortium is a clinically and cognitively well-characterized cohort of patients with PD. Baseline cohort characteristics demonstrate a high rate of cognitive impairment in the sample, as well as potential sex differences with regard to cognitive diagnosis. The PANUC Clinical Consortium, with its access to biomarker, genetic, and autopsy data, provides an excellent foundation for detailed research related to cognitive impairment in PD.
BACKGROUND: The substantial proportion of individuals with Parkinson's disease (PD) who have or are expected to develop concomitant cognitive impairment emphasizes the need for large, well-characterized participant cohorts to serve as a basis for research into the causes, manifestations, and potential treatments of cognitive decline in those with PD. OBJECTIVE: To establish a multi-site clinical core that cognitively and clinically characterizes patients with PD by obtaining quality longitudinal clinical, neuropsychological, and validated biomarker data. METHODS: Six hundred nineteen participants with idiopathic PD (68.0 ± 9.1 years, 7.1 ± 6.2 years since diagnosis, 70% males) were enrolled in the Pacific Northwest Udall Center (PANUC), one of the Morris K. Udall Centers of Excellence for Parkinson's Research, Clinical Consortium and underwent comprehensive clinical and neuropsychological assessment. Participants were diagnosed with no cognitive impairment (PD-NCI), mild cognitive impairment (PD-MCI), or dementia (PDD) at a diagnostic consensus conference. RESULTS: A substantial proportion of the overall sample was diagnosed with cognitive impairment at baseline: 22% with PDD and 59% with PD-MCI. A higher rate of cognitive impairment was observed in men than women (87% vs. 68%, p < 0.0001), despite a higher level of education. Most patients older than 50 years at the time of diagnosis and with disease duration greater than 10 years were cognitively impaired or demented. CONCLUSIONS: The PANUC Clinical Consortium is a clinically and cognitively well-characterized cohort of patients with PD. Baseline cohort characteristics demonstrate a high rate of cognitive impairment in the sample, as well as potential sex differences with regard to cognitive diagnosis. The PANUC Clinical Consortium, with its access to biomarker, genetic, and autopsy data, provides an excellent foundation for detailed research related to cognitive impairment in PD.
Authors: G Li; E B Larson; J A Sonnen; J B Shofer; E C Petrie; A Schantz; E R Peskind; M A Raskind; J C S Breitner; T J Montine Journal: Neurology Date: 2007-08-28 Impact factor: 9.910
Authors: G Stennis Watson; Brenna A Cholerton; Rachel G Gross; Daniel Weintraub; Cyrus P Zabetian; John Q Trojanowski; Thomas J Montine; Andrew Siderowf; James B Leverenz Journal: Alzheimers Dement Date: 2012-11-16 Impact factor: 21.566
Authors: Sandra Weintraub; David Salmon; Nathaniel Mercaldo; Steven Ferris; Neill R Graff-Radford; Helena Chui; Jeffrey Cummings; Charles DeCarli; Norman L Foster; Douglas Galasko; Elaine Peskind; Woodrow Dietrich; Duane L Beekly; Walter A Kukull; John C Morris Journal: Alzheimer Dis Assoc Disord Date: 2009 Apr-Jun Impact factor: 2.703
Authors: Joan Lindsay; Danielle Laurin; René Verreault; Réjean Hébert; Barbara Helliwell; Gerry B Hill; Ian McDowell Journal: Am J Epidemiol Date: 2002-09-01 Impact factor: 4.897
Authors: Ignacio F Mata; James B Leverenz; Daniel Weintraub; John Q Trojanowski; Alice Chen-Plotkin; Vivianna M Van Deerlin; Beate Ritz; Rebecca Rausch; Stewart A Factor; Cathy Wood-Siverio; Joseph F Quinn; Kathryn A Chung; Amie L Peterson-Hiller; Jennifer G Goldman; Glenn T Stebbins; Bryan Bernard; Alberto J Espay; Fredy J Revilla; Johnna Devoto; Liana S Rosenthal; Ted M Dawson; Marilyn S Albert; Debby Tsuang; Haley Huston; Dora Yearout; Shu-Ching Hu; Brenna A Cholerton; Thomas J Montine; Karen L Edwards; Cyrus P Zabetian Journal: Mov Disord Date: 2015-08-21 Impact factor: 10.338
Authors: V E Kelly; C O Johnson; E L McGough; A Shumway-Cook; F B Horak; K A Chung; A J Espay; F J Revilla; J Devoto; C Wood-Siverio; S A Factor; B Cholerton; K L Edwards; A L Peterson; J F Quinn; T J Montine; C P Zabetian; J B Leverenz Journal: Parkinsonism Relat Disord Date: 2015-04-14 Impact factor: 4.891
Authors: Tara M Madhyastha; Mary K Askren; Jing Zhang; James B Leverenz; Thomas J Montine; Thomas J Grabowski Journal: Brain Date: 2015-07-14 Impact factor: 13.501
Authors: Krista Specketer; Cyrus P Zabetian; Karen L Edwards; Lu Tian; Joseph F Quinn; Amie L Peterson-Hiller; Kathryn A Chung; Shu-Ching Hu; Thomas J Montine; Brenna A Cholerton Journal: J Clin Exp Neuropsychol Date: 2019-06-10 Impact factor: 2.475
Authors: Taylor R Hendershott; Delphine Zhu; Seoni Llanes; Cyrus P Zabetian; Joseph Quinn; Karen L Edwards; James B Leverenz; Thomas Montine; Brenna Cholerton; Kathleen L Poston Journal: Mov Disord Date: 2018-12-10 Impact factor: 10.338
Authors: Nicole Licking; Charles Murchison; Brenna Cholerton; Cyrus P Zabetian; Shu-Ching Hu; Thomas J Montine; Amie L Peterson-Hiller; Kathryn A Chung; Karen Edwards; James B Leverenz; Joseph F Quinn Journal: Parkinsonism Relat Disord Date: 2017-08-09 Impact factor: 4.891
Authors: Ignacio F Mata; Catherine O Johnson; James B Leverenz; Daniel Weintraub; John Q Trojanowski; Vivianna M Van Deerlin; Beate Ritz; Rebecca Rausch; Stewart A Factor; Cathy Wood-Siverio; Joseph F Quinn; Kathryn A Chung; Amie L Peterson-Hiller; Alberto J Espay; Fredy J Revilla; Johnna Devoto; Dora Yearout; Shu-Ching Hu; Brenna A Cholerton; Thomas J Montine; Karen L Edwards; Cyrus P Zabetian Journal: Neurobiol Aging Date: 2017-04-20 Impact factor: 4.673
Authors: Min Shi; Andrej Kovac; Ane Korff; Travis J Cook; Carmen Ginghina; Kristin M Bullock; Li Yang; Tessandra Stewart; Danfeng Zheng; Patrick Aro; Anzari Atik; Kathleen F Kerr; Cyrus P Zabetian; Elaine R Peskind; Shu-Ching Hu; Joseph F Quinn; Douglas R Galasko; Thomas J Montine; William A Banks; Jing Zhang Journal: Alzheimers Dement Date: 2016-05-24 Impact factor: 21.566
Authors: Min Shi; Changqin Liu; Travis J Cook; Kristin M Bullock; Yanchun Zhao; Carmen Ginghina; Yanfei Li; Patrick Aro; Romel Dator; Chunmei He; Michael J Hipp; Cyrus P Zabetian; Elaine R Peskind; Shu-Ching Hu; Joseph F Quinn; Douglas R Galasko; William A Banks; Jing Zhang Journal: Acta Neuropathol Date: 2014-07-06 Impact factor: 17.088
Authors: Wojciech Gryc; Kathryn A Roberts; Cyrus P Zabetian; Daniel Weintraub; John Q Trojanowski; Joseph F Quinn; Amie L Hiller; Kathryn A Chung; Kathleen L Poston; Laurice Yang; Shu-Ching Hu; Karen L Edwards; Thomas J Montine; Brenna A Cholerton Journal: J Parkinsons Dis Date: 2020 Impact factor: 5.568